相关实验视频

Updated: May 1, 2026

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

选择性血清素再吸收抑制剂和骨质疏松症:一个使用真实世界数据的目标试验模拟

Christopher Rohde^1,2, Lana J Williams³, Michael Berk³

¹Department of Affective Disorders, Aarhus University Hospital - Psychiatry, Aarhus, Denmark.

Acta neuropsychiatrica

|March 10, 2025

概括

选择性血清素再吸收抑制剂 (SSRI) 像塞特拉林,西塔洛普拉姆和埃斯基塔洛普拉姆不会对骨质疏松症风险产生差异性影响. 这些SSRI似乎不会因果增加骨质疏松症风险,即使剂量不同.

科学领域:

药物监督药物监督药物监督
骨健康研究骨健康研究
流行病学流行病学

背景情况:

选择性血清素再吸收抑制剂 (SSRI) 广泛用于治疗抑郁症.
以前的研究表明,SSRI使用与骨质疏松症风险增加之间存在潜在的关联.
有关特定SSRI之间的差异性影响存在担忧,例如塞特拉林与西塔洛普拉姆.

研究的目的:

调查塞特拉林,西塔洛普拉姆和埃斯基塔洛普拉姆是否对骨质疏松症风险产生不同影响.
检查SSRI使用和骨质疏松症之间的潜在剂量反应关系.
为有关骨健康的SSRI安全提供基于证据的见解.

主要方法:

使用丹麦全国性注册 (2007-2019) 的目标试验模拟.
包括开始使用塞特拉林,西塔洛普拉姆或埃斯基塔洛普拉姆治疗的个人.
考克斯比例危险回归用于比较骨质疏松症的发病率,并评估剂量反应关系.

主要成果:

在使用塞特拉林,西塔洛普拉姆和埃斯基塔洛普拉姆的患者之间没有观察到统计学上显著的骨质疏松症风险差异.
调整后的危险率比率 (aHRR) 没有显著差异 (例如,citalopram和sertraline的aHRR=0.98).
没有证据表明这些SSRI对骨质疏松症风险的剂量反应效应.

结论:

塞特拉林,西塔洛普拉姆和埃斯基塔洛普拉姆似乎对骨质疏松症风险没有差异性影响.
缺乏明确的剂量反应关系表明这些SSRI可能在骨质疏松症中没有因果作用.
这些发现有助于理解常见抗抑郁药物对骨健康的影响.

关键词:

抗抑郁药是一种抗抑郁药.抑郁抑郁症抑郁症抑郁症是一种流行病学流行病学骨质疏松症是一种骨质疏松症.选择性血清素再吸收抑制剂选择性血清素再吸收抑制剂

更多相关视频

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model

Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model

Published on: September 28, 2017

相关概念视频

Osteoclasts in Bone Remodeling

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...